Seeking Alpha

Alnylam (ALNY -0.7%) announces positive results from a pre-clinical ex vivo study, which takes...

Alnylam (ALNY -0.7%) announces positive results from a pre-clinical ex vivo study, which takes place outside the organism, that could lead to the development of improved cellular vaccines for cancer and chronic viral infections. Alnylam's focus is RNA interference (RNAi), or the study of how genes are turned on and off in cells. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector